Results 21 to 30 of about 131,732 (302)

In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.

PLoS ONE, 2012
Telomerase is a specialized reverse transcriptase responsible for the de novo synthesis of telomeric DNA repeats. In addition to its established reverse transcriptase and terminal transferase activities, recent reports have revealed unexpected cellular ...
Kyle R Hukezalie, Naresh R Thumati, Hélène C F Côté, Judy M Y Wong   +3 more
doaj   +1 more source

The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase [PDF]

Trends in Pharmaceutical Sciences
HIV-1 reverse transcriptase (RT) is a crucial enzyme in HIV replication and AIDS progression. It consists of p66 and p51 subunits and converts viral RNA into double-stranded DNA for integration into the host cell's genome.
Roohallah Yousefi
doaj   +1 more source

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance

Scientifica, 2012
The use of highly active antiretroviral therapy (HAART) involves combinations of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance.
Mark A. Wainberg
doaj   +1 more source

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads [PDF]

, 2006
Background. Our objective was to compare the rate of viral rebound and therapy failure in patients receiving abacavir or efavirenz as the third drug ( in addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy ( cART) and to compare
Phillips, AN, L. Sighinolfi, D'ARMINIO MONFORTE A, R. Cauda, MOIOLI MC, Monforte, AD, COZZI-LEPRI A, DI GIAMBENEDETTO S, M. Mena, Sighinolfi, L, SIGHINOLFI L, A. Cozzi Lepri, Lichtner, M, ICoNA Study Group, Arlotti, M, M. Lichtner, Bongiovanni, M, Mena, M, M. Arlotti, UCSC Roma HIV Cohort Study Group, CAUDA R, A. N. Phillips, De Luca, A, Di Giambenedetto, S, Cozzi-Lepri, A, DE LUCA A, BONGIOVANNI M, PHILLIPS AN, UCSC-Roma HIV Cohort Study Grp, Narciso, P, Cauda, R, IMIT Study Grp, IMIT Study Group, A. De Luca, ICoNA Study Grp, MENA M, ARLOTTI M, NARCISO P, LICHTNER M, M. C. Moioli, Moioli, MC, S. Di Giambenedetto, P. Narciso, M. Bongiovanni, A. d’Arminio Monforte   +44 more
core   +1 more source

Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [PDF]

Journal of Advanced Pharmacy Research
Objectives: The nucleic acid-binding cleft in HIV-1 reverse transcriptase (HIV-1 RT) is essential because of its interactions with the polymerase and RNase H active sites. Studying its binding sites for nucleoside reverse transcriptase inhibitors (NRTIs)
Roohallah Yousefi
doaj   +1 more source

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? [PDF]

, 2011
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can ...
Braun, Patrick, Ehret Robert, Naeth, Gudrun, Frank Wiesmann, Tappe André, Tappe, André, Rolf Kaiser, Martin Stürmer, Hauke Walter, Jan Vachta, Walter, Hauke, André Tappe, Ehret, Robert, Stürmer Martin, Thomas Berg, Kaiser Rolf, Robert Ehret, Berg Thomas, Naeth Gudrun, Knechten Heribert, Gudrun Naeth, Patrick Braun, Knechten, Heribert, Stürmer, Martin, Wiesmann, Frank, Vachta, Jan, Heribert Knechten, Kaiser, Rolf, Berg, Thomas, Walter Hauke, Martin Däumer, Braun Patrick, Däumer Martin, Wiesmann Frank, Vachta Jan, Däumer, Martin   +35 more
core   +1 more source

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs

Nature Communications, 2021
Initiation of HIV-1 reverse transcription occurs at the host tRNALys 3, which forms a complex with the 5’ end of the HIV-1 viral RNA and reverse transcriptase (RT).
Betty Ha, Kevin P. Larsen, Jingji Zhang, Ziao Fu, Elizabeth Montabana, Lynnette N. Jackson, Dong-Hua Chen, Elisabetta Viani Puglisi   +7 more
doaj   +1 more source

Methoxyflavones from as HIV-1 Reverse Transcriptase Inhibitors

Natural Product Communications, 2017
Methoxyflavones are flavonoid widely distributed in plants and has been reported as potent antitumor agents and some of them have shown activity against HIV-1. In this work, two methoxyflavones isolated from Marcetia taxifolia were evaluated in vitro and
Joseph T Ortega, María Luisa Serrano, Alírica I Suárez, Jani Baptista, Flor H Pujol, Héctor R Rangel   +5 more
doaj   +1 more source

Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002

Annals of Clinical Microbiology and Antimicrobials, 2003
Background The prices of reverse transcriptase (RT) inhibitors in Thailand have been reduced since December 1, 2001. It is expected that reduction in the price of these inhibitors may influence the drug resistance mutation pattern of HIV-1 among infected
Watitpun Chotip, Jenwitheesuk Ekachai, Vibhagool Asda, Chantratita Wasun   +3 more
doaj   +1 more source

Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data

Cells, 2021
Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic.
Ashley O. Otto, Christina G. Rivera, John D. Zeuli, Zelalem Temesgen   +3 more
doaj   +1 more source